3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Dermatologic
1
Conditions
Melanoma
4
Carcinoma, Basal Cell
4
Sarcoma, Kaposi
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Interventions
Doxorubicin
10
Zidovudine
9
Vincristine
7
Bleomycin
7
Nivolumab
6
Liposomes
5
Interferon alpha-2
5
Etoposide
5
tecogalan
4
pembrolizumab
4
liposomal doxorubicin
4
Valganciclovir
4
Specimen Handling
4
Semaxinib
4
Paclitaxel
4
Nelfinavir
4
Magnetic Resonance Spectroscopy
4
pomalidomide
3
Ritonavir
3
Filgrastim
3
Biopsy
3
Bevacizumab
3
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
2
sargramostim
2
interferon alfa-n1
2
Propranolol
2
Indinavir
2
Docetaxel
2
Didanosine
2
Daunorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Sarcoma, Kaposi
×
daromun
×
Clear all
NCT05329792
2023-10-06
IntriNSiC
Philogen S.p.A.
Phase 2
Unknown
70 enrolled